INO
Inovio Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.40
+2.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 65.3K | 217.8K | 832.0K | 10.3M |
| Cost of Revenue | 1.5M | — | — | — | — |
| Gross Profit | (1.5M) | 65.3K | 217.8K | 832.0K | 10.3M |
| Operating Expenses | |||||
| R&D Expense | 48.2M | 54.2M | 75.6M | 86.7M | 187.7M |
| SG&A Expense | 7.9B | 32.7M | 37.0M | 47.6M | 90.2M |
| General & Admin Expense | 7.9B | 32.7M | 37.0M | 47.6M | 90.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (7.9B) | — | — | 10.5M | — |
| Total Operating Expenses | 77.8M | 86.9M | 112.6M | 144.8M | 277.8M |
| Cost and Expenses | 79.3M | 86.9M | 112.6M | 144.8M | 277.8M |
| Operating Income (EBIT) | (79.3M) | (86.8M) | (112.4M) | (143.9M) | (267.6M) |
| Non-Operating | |||||
| Interest Income | 553.4M | 2.4M | 4.8M | 8.1M | 4.8M |
| Interest Expense | — | — | 177.8K | 1.2M | 1.3M |
| Net Interest Income | 553.4M | 2.4M | 4.6M | 6.9M | 3.5M |
| Other Non-Op Income/Expense | 11.8M | 1.9M | 5.1M | 8.8M | (12.2M) |
| Non-Operating Income (excl Interest) | (11.8M) | (1.9M) | (5.3M) | (10.0M) | 8.8M |
| EBT (Pre-Tax Income) | (67.4M) | (84.9M) | (107.3M) | (135.1M) | (279.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (67.4M) | (84.9M) | (107.3M) | (135.1M) | (279.8M) |
| Earnings from Cont. Ops | (67.4M) | (84.9M) | (107.3M) | (135.1M) | (279.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (67.4M) | (84.9M) | (107.3M) | (135.1M) | (279.8M) |
| Per Share | |||||
| Basic EPS | ($1.17) | ($1.81) | ($3.95) | ($6.09) | ($14.07) |
| Diluted EPS | ($1.17) | ($1.81) | ($3.95) | ($6.09) | ($14.07) |
| Revenue Per Share | $0.00 | $0.00 | $0.01 | $0.04 | $0.52 |
| Shares | |||||
| Basic Shares Outstanding | 81.6M | 46.9M | 27.2M | 22.2M | 19.9M |
| Diluted Shares Outstanding | 81.6M | 46.9M | 27.2M | 22.2M | 19.9M |
| Profitability Metrics | |||||
| EBITDA | (64.9M) | (82.0M) | (103.9M) | (130.4M) | (270.9M) |
| D&A | 2.6M | 3.0M | 3.1M | 3.5M | 5.5M |
| EBIT | (67.4M) | (84.9M) | (107.1M) | (133.9M) | (276.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026